AADAC Antibody

Catalog No: #36000

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	AADAC Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antigen affinity purification.
Applications	WB IHC
Species Reactivity	Hu
Specificity	The antibody detects endogenous levels of total AADAC protein.
Immunogen Type	Recombinant Protein
Immunogen Description	Fusion protein corresponding to residues near the C terminal of human Arylacetamide deacetylase
Target Name	AADAC
Other Names	DAC; CES5A1
Accession No.	Swiss-Prot#: P22760NCBI Gene ID: 13Gene Accssion: BC032309
Uniprot	P22760
GeneID	13;
SDS-PAGE MW	46kd
Concentration	1.4mg/ml
Formulation	Rabbit IgG in pH7.4 PBS, 0.05% NaN3, 40% Glycerol.
Storage	Store at -20°C

Application Details

Western blotting: 1:500-1:2000

Immunohistochemistry: 1:50-1:100

Images



Gel: 10%SDS-PAGE
Lysates (from left to right): Human fetal liver and liver cancer tissue
Amount of lysate: 40ug per lane
Primary antibody: 1/600 dilution
Secondary antibody dilution: 1/8000
Exposure time: 1 minute



Immunohistochemical analysis of paraffin-embedded Human liver cancer tissue using #36000 at dilution 1/30.

Background

Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens. Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide, which is an antiandrogen drug used for the treatment of prostate cancer that occasionally causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.

Note: This product is for in vitro research use only